Cargando…
SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature
Myasthenia gravis (MG) is an antibody-mediated immune disorder of the neuromuscular junction. SARS-CoV-2 is now recognised as a trigger factor for autoimmune diseases and to cause immune-mediated dysregulation, likely due to molecular mimicry induced by viral antigens. SARS-CoV-2 vaccination, simila...
Autores principales: | Ramdas, Sithara, Hum, Ryan Malcolm, Price, Abigail, Paul, Anna, Bland, Jeremy, Burke, Georgina, Farrugia, Maria, Palace, Jacqueline, Storrie, Alice, Ho, Pauline, Standing, Emma, Lilleker, James B., Jungbluth, Heinz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443923/ https://www.ncbi.nlm.nih.gov/pubmed/36130855 http://dx.doi.org/10.1016/j.nmd.2022.09.001 |
Ejemplares similares
-
Management of Juvenile Myasthenia Gravis
por: O'Connell, Karen, et al.
Publicado: (2020) -
Myasthenia gravis: a clinical-immunological update
por: Binks, Sophie, et al.
Publicado: (2015) -
Myasthenia Gravis with Elderly Onset at Advanced Age
por: Hernandez Fustes, Otto Jesus, et al.
Publicado: (2020) -
Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007) -
Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)